The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 /PRNewswire/ ...

LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong ...

If drug developers are allowed to skip this step, it will mean that, in the near future, the first living body a new drug is ...

Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration- Trial to assess safety, PK and detect early signs of efficacy- Initial data expected in mid-2026 ...

The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 ...

Procedural flexibility incorporated into many cancer clinical trials during the COVID-19 pandemic had no long-term negative ...

A first-of-its-kind solution for women’s arousal in a proprietary topical formulation demonstrated to work where women need ...

On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose ...

Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single ...

Nations that lead in clinical trials get earlier access to breakthrough therapies, shape global regulatory norms, and ...

Decentralized Clinical Trials (DCTs) are transforming how we collect clinical data, but this evolution brings unprecedented challenges in data quality, complexity, and integration.